The application of immunotherapy for cancer treatment is rapidly becoming more
widespread. Immunotherapeutic agents are frequently combined with various types of …

Gastric cancer (GC) is a highly aggressive malignancy that remains a significant contributor
to cancer-related mortality worldwide, despite a decline in incidence in recent years. Early …

BACKGROUND Gastric cancer (GC) is the sixth most common cancer and third leading
cause of cancer-related deaths worldwide. Current treatments mainly rely on surgery-and …

HER2-positive gastroesophageal adenocarcinomas (GEAs) are common cancers with high
mortality and the treatment options for advanced/metastatic disease are limited …

Gastric cancer is an aggressive disease with increasing global incidence in recent years.
Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10–20% of …

The new era of immunotherapy is successfully implemented in the treatment of
metastatic/locally advanced esophagogastric adenocarcinoma (EGAC), as it has been …

Simple Summary The human epidermal growth factor receptor 2 (HER2) became the first
routinely targeted biomarker in the management of stomach cancers when the monoclonal …

Esophageal cancers have a high mortality rate and limited treatment options especially in
the advanced/metastatic setting. Squamous cell carcinoma (SCC) and adenocarcinoma are …

Gastric cancer is an extremely common digestive tract tumor. The promotion and application
of standardized therapy, treatment scheme optimization, and development of new targeted …

Purpose: We report updated clinical outcomes from a phase II study of pembrolizumab,
trastuzumab, and chemotherapy (PTC) in metastatic esophagogastric cancer in conjunction …